Synovial sarcoma: characteristics, challenges, and evolving therapeutic strategies

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Synovial sarcoma (SS) is a rare, aggressive soft tissue sarcoma, primarily affecting young adults.
• The SS18::SSX fusion oncogene, resulting from a specific chromosomal translocation, drives over 95% of SS cases.
• Early diagnosis and multidisciplinary management are crucial for optimal outcomes.

Purpose of the Study:

• To review the epidemiology, characteristics, and patient journey of synovial sarcoma.
• To summarize current and future management strategies for SS.
• To highlight the potential of novel therapies, particularly immunotherapies, for advanced disease.

Main Methods:

• Literature review of synovial sarcoma epidemiology, pathology, and treatment.
• Analysis of current treatment modalities for localized and advanced SS.
• Exploration of emerging targeted agents and immunotherapies in clinical trials.

Main Results:

• SS predominantly affects younger individuals, with a peak incidence in the fourth decade.
• Localized SS can be treated effectively with surgery and multimodal therapy, especially in children.
• Advanced SS has a poor prognosis with conventional chemotherapy, necessitating new approaches.

Conclusions:

• There is a significant unmet need for effective treatments for advanced synovial sarcoma.
• Advances in understanding SS molecular pathology are enabling the development of targeted therapies.
• Immunotherapies represent a promising avenue for improving clinical outcomes in advanced SS.